$CYDY} CytoDyn and Samsung BioLogics Enter into Agreement to Manufacture $1 Billion Worth of Leronlimab (PRO 140) to Meet Expected Demand for Future Revenues Post-Approval “We are elated at the distinction of partnering with the world’s preeminent biologics manufacturer for our franchise-defining drug,” stated Nader Pourhassan, Ph.D, CytoDyn’s President, CEO and director.  {{Press release @ Upticknewswire.com}